You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023262018
Dec 20236206
Jan 20244302
Feb 20246604
Mar 20242000
Apr 20245009
May 20243602
Jun 20244801
Jul 20241801
Aug 20243606
Sep 20243401
Oct 20245605
Nov 20245005
Dec 20247604
Jan 20254308
Feb 20251205
Mar 2025003
Apr 2025004
May 2025009
Jun 2025002
Total912095